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Abstract
Rationale Successive negative contrast (SNC) describes a
change in the behaviour of an animal following a downshift
in the quantitative or qualitative value of an expected reward.
This behavioural response has been hypothesised to be linked
to affective state, with negative states associated with larger
and/or prolonged shifts in behaviour.
Objective This study has investigated whether different psy-
chopharmacological treatments have dissociable actions on
the SNC effect in rats and related these findings to their ac-
tions on different neurotransmitter systems and affective state.
Methods Animals were trained to perform a nose-poke re-
sponse to obtain a high-value food reward (four pellets).
SNC was quantified during devalue sessions in which the
reward was reduced to one pellet. Using a within-subject
study design, the effects of acute treatment with anxiolytic,
anxiogenic, antidepressant and dopaminergic drugs were in-
vestigated during both baseline (four pellets) or devalue ses-
sions (one pellet).
Results The indirect dopamine agonist, amphetamine, at-
tenuated the SNC effect whilst the D1/D2 antagonist,
alpha-flupenthixol, potentiated it. The antidepressant
citalopram, anxiolytic buspirone and anxiogenic FG7142
had no specific effects on SNC, although FG7142 induced
general impairments at higher doses. The α2-adrenoceptor
antagonist, yohimbine, increased premature responding but
had no specific effect on SNC. Results for the anxiolytic di-
azepamwere mixed with one group showing an attenuation of
the SNC effect whilst the other showed no effect.
Conclusions These data suggest that the SNC effect is medi-
ated, at least in part, by dopamine signalling. The SNC effect
may also be attenuated by benzodiazepine anxiolytics.
Keywords Anxiety . Antidepressant . Affective state .
Behaviour .Monoamine transmitters
Introduction
Sensitivity to gain or loss of reward has significant impact
upon functioning of an individual (Wenzlaff and Grozier
1988). Generally, there is a greater sensitivity to reward loss
than gain (Dreher 2007) and heightened sensitivity to loss, and
failure is proposed to be a feature of negative affective states
(Hajcak et al. 2004). Therefore, evaluating the sensitivity to
reward loss in animals could provide an objective measure of
affective state and emotion-related behaviours (Paul et al.
2005). Successive negative contrast (SNC) is defined as the
behavioural response to a decrease in quantity or quality of
reward (Crespi 1942). To be considered an SNC effect, per-
formance measures e.g. response latencies or amount con-
sumed, in response to a reduced value of the expected reward
must fall below that of control animals that have only ever
been exposed to the lower reward value (Crespi 1942). If the
downshifted animals continue to receive the lower value of
reward for several days, their performance typically returns to
the level of control animals (Flaherty 1996). As such, it has
been suggested that this ‘overshoot’ in response represents the
emotional response to the reduced reward. This hypothesis is
supported to some extent by studies investigating the SNC
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effect in animals exposed to modified housing conditions
(Burman et al. 2008; Mitchell et al. 2012).
The SNC effect has been demonstrated using a number of
different methods including consummatory (Mitchell and
Flaherty 2005) and instrumental runway or lever press
(Rosas et al. 2007) appetitive tasks and an aversive one-way
avoidance task (Morales et al. 1992). In these tasks, the SNC
effect is induced by reducing the relative value of the outcome
received during sessions referred to as ‘devalue’ sessions.
Previous work in our laboratory has developed and evaluated
an appetitive operant chamber SNC task based on animals
making a nose-poke response for reward (Mitchell et al.
2012). Similar to the five-choice serial reaction time task
(5CSRTT) (Robbins 2002; Bari et al. 2008) but only using
the central aperture, rats are trained to nose-poke in response
to a light cue presented after a fixed intertrial interval (ITI), to
receive four (baseline sessions) or one (devalue sessions) re-
ward pellet(s). As there is only a single aperture used, the
visuospatial element of the 5CSRTT is removed; however,
the method still facilitates a dissociation between motivation
to respond to a cue and motivation to collect reward (Robbins
2002), as well as other measures such as anticipatory re-
sponses (responses made during the intertrial interval and be-
fore the light cue) and omissions (attention). In our method,
animals are trained to a stable baseline performance with the
devalue session presented in a single test session and repeated
once per week. This also means that animals can be tested
over multiple sessions allowing for within-subject compari-
sons where an individual animal can be tested during both a
baseline and devalue session and following multiple drug
doses. We have previously shown that this approach leads to
a clear SNC effect with animals in the devalue group
exhibiting reduced response and collection latencies as well
as increased omissions and reduced anticipatory responses
(Mitchell et al. 2012). The animals also show a shift in laten-
cies which falls below that of animals which only ever re-
ceived a one-pellet reward during the same basic task
(Mitchell et al. 2012).
Previous investigations have tended to show that the SNC
effect is influenced by benzodiazepines (Flaherty 1990, 1996).
However, the effects of antidepressants are less clear with
either attenuation, facilitation or no effect on the SNC ob-
served (Flaherty 1990; Flaherty et al. 1990; Nikiforuk and
Popik 2009). To further investigate the psychopharmacology
of the SNC effect, we have tested a number of compounds
acting through different neurochemical mechanisms in an op-
erant SNC task. The first set of experiments focused on com-
pounds known to induce either anxiolytic or anxiogenic ef-
fects in humans by acting on benzodiazepine receptors or
targeting the serotonin system. In addition to these com-
pounds, we have also tested the α2-adrenoceptor antagonist,
yohimbine, which has been shown to induce anxiety-like be-
haviours in animals (Cai et al. 2012). In order to understand
more about the neurochemical mechanisms which contribute
to the SNC effect, the final set of experiments investigated the
effects of the indirect dopamine agonist, amphetamine, and
mixed D1/D2 receptor antagonist, alpha-flupenthixol. The
role of dopamine in the SNC effect was investigated because
previous studies have found that the SNC effect is potentiated
during withdrawal from the psychostimulant amphetamine
(Barr and Phillips 2002).
Materials and methods
Animals
The subjects were two cohorts of male Lister hooded rats (n=
12 animals in each cohort, both Harlan, UK) weighing approx-
imately 250 g at the start of training and 350–450 g at the start
of testing. They were housed in pairs, under temperature-
controlled conditions and 12:12-h reverse light–dark cycle
(lights off at 0800). Rats were food restricted to maintain them
at approximately 90% of their free-feedingweights by limiting
daily intake of laboratory chow to approximately 18 g per rat
per day. Water was provided ad libitum. Principles of animal
laboratory care were followed, and all procedures were con-
ducted in accordancewith the requirements of the UKAnimals
(Scientific Procedures) Act 1986 and in accordance with local
institutional guidelines. All behavioural testing was carried out
between 0800 and 1700 during the animals’ active phase.
Training and testing
All behavioural training and testing was carried out using five-
hole operant chambers (Med Associates, VT, USA) and con-
trolled by K-Limbic software (Conclusive solutions Ltd, UK).
Animals were trained under the schedule previously described
(Mitchell et al. 2012). Briefly, training consisted of a graduat-
ed procedure similar to the one used for the 5CSRTT (Bari
et al. 2008). The animals were trained to initiate the trial by
making a nose-poke response in the reward magazine. After
an ITI, they had to make a nose-poke response to a light cue in
the central aperture within a fixed limited hold (LH) after
which they could collect their reward (1 or 4×40 mg Noyes
precision pellet, Sandown Scientific) from the magazine.
Animals were trained using a seven-stage graduated proce-
dure where each stage of training consisted of an increasing
ITI, decreasing LH and decreasing stimulus duration (Mitchell
et al. 2012). Training started at stimulus duration=60 s, ITI=
2 s and LH=60 s. Once animals had achieved criterion (>20
trials completed) for two consecutive sessions, the stimulus
duration and LH were reduced, and the ITI increased to the
next stage. This continued with the same criterion until ITI=
20 s, stimulus=10 s and LH=10 s, and they completed >20
correct trials in two consecutive sessions at this level.
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Four parameters were measured: correct latency (the time
between stimulus onset and correct nose-poke response), col-
lection latency (the time from correct response to collection of
food reward), omissions (failing to respond within the ITI) and
premature responses (response made prior to cued stimulus).
Correct trials were recorded but as all animals completed all
trials in all studies, these were not analysed further. As only a
single aperture was used and all animals completed all trials,
only data for omissions were analysed. All animals (n=12 in
two separate cohorts) were trained to receive a four-pellet
reward for a correct response. Both premature and omitted
responses were punished with a 5-s timeout where all lights
were extinguished. Following training and 10-day baseline
testing with the four-pellet reward, devalue sessions were in-
troduced in which all animals received only one pellet for a
correct response. These devalue sessions were repeated once
weekly (Friday) for 3 weeks in total.
During testing, animals were treated with the drug or vehi-
cle prior to each of the session types (baseline=4 pellets or
devalue=1 pellet). To control for non-specific effects and to
facilitate comparisons between session types, each animal re-
ceived all doses in a pseudorandomised study design which
included randomisation of both dose and session type.
Drug study protocol
Prior to each of the drug studies, animals were given a week
baseline testing with one devalue session (devalue session on a
Friday). After each drug study, the animals were given at least
1-week washout without drug treatment and at least five ses-
sions under baseline (four-pellet reward) conditions. Each drug
study was run under a counterbalanced within-subject design
where each animal received each treatment prior to a baseline
and devalue test session. Baseline drug testing was carried out
on a Tuesday, and devalue sessions were run on a Friday with
animals being run under baseline conditions without treatment
on Monday, Wednesday and Thursday. Doses of drugs were
based on previous SNC and 5CSRTTstudies or doses shown to
have anxiolytic or anxiogenic effects in other rodent tasks
(Stuart et al. 2013; Torres et al. 1995; Yeung et al. 2013; Cai
et al. 2012; Hayton et al. 2012; Cole and Robbins 1987). The
first cohort of animals received a total of 16 treatments with
drugs in the following order: diazepam (0.0, 0.3 and 1.0mg/kg),
buspirone (0.0, 1.0 and 3.0 mg/kg), citalopram (0.0, 0.3 and
1.0 mg/kg), yohimbine (0.0, 1.0, 3.0 and 6.0 mg/kg) and
FG7142 (0.0, 3.0 and 5.5 mg/kg). The second cohort of ani-
mals was tested with the following drugs in order: amphet-
amine (0.0, 0.1 and 0.3 mg/kg), alpha-flupenthixol (0.0, 0.1
and 0.3 mg/kg) and diazepam (0.0, 0.3 and 1.0 mg/kg). All
drugs were administered intraperitoneally with a 30-min pre-
treatment time except amphetamine (pretreatment 20 min) and
alpha-flupenthixol (pretreatment time 60 min). Animals were
returned to home cages after dosing until 5 min prior to testing.
Drugs
Yohimbine hydrochloride (Tocris, UK) was dissolved in
distilled water. Citalopram hydrobromide (Tocris, UK),
buspirone hydrochloride (Sigma, UK) amphetamine (Sigma,
UK) and alpha-flupenthixol (Sigma, UK) were dissolved in
0.9 % saline. FG7142 (β-carboline-3-carboxylic acid N-
methylamide) and diazepam (both Sigma, UK)were dissolved
in 10 % dimethyl sulphoxide (DMSO; BDH Laboratory
Supplies, UK), 20 % cremophor EL (Sigma, UK) and
70 % of 0.9 % saline. All drugs were administered at a final
volume of 1 ml/kg.
Statistical analysis
All graphs were plotted using Graphpad Prism (version 5.0),
and statistical analyses were performed using SPSS (version
21). Correct latency, collection latency, percent premature
responses and percent omitted responses were recorded
and analysed using repeated measures ANOVAs with
SESSION (baseline or devalue) and DOSE (vehicle or
drug at each dose) as within-subject factors. A Bonferroni
confidence interval adjustment was used to compare main
effects. Where significant main effects or interactions
(p<0.05) were observed post hoc, pairwise comparisons
were made using two-tailed t-tests between vehicle
baseline and vehicle devalue sessions and between ve-
hicle and drug doses within each session type. Results
with an alpha <0.1 were also considered as trend level
effects and are discussed within the result section. A Huynh-
Feldt correction was used to adjust for violation of the sphe-
ricity assumption.
Results
Baseline performance during the testing period
To check for stability in performance over the course of
the studies, the predrug and between drug baseline data
were analysed using a repeated measures ANOVA with
TIME as a factor. There was no effect of TIME for
correct or collection latencies or omissions (F<0.78,
p>0.54), but there was a significant effect of TIME
for premature responding (F (3.375, 37.127)=3.681 p=
0.017) in cohort 1. Post hoc comparison did not reveal
an overall trend in any particular direction (test week 1
vs test week 5 were not significantly different), but a
higher degree of variability was seen with this measure.
There were no effects of TIME for any of the variables
in cohort 2 (F<2.4, p>0.12).
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Effects of acute administration of anxiolytic
and antidepressant drug treatments
Diazepam Diazepam showed a tendency to attenuate the de-
value effect. In both cohorts of animals tested, there was an
effect of devaluation with a main effect of SESSION for cor-
rect latency (F(1, 11)=12.23, p=0.005, Fig. 1a; F(1, 10)=
28.872, p<0.001, Fig. 2a) and collection latency (F(1, 11)=
38.65, p<0.001, Fig. 1b; F(1, 10)=66.41, p<0.001, Fig. 2b).
Post hoc pairwise comparisons revealed a devalue effect be-
tween vehicle-treated baseline and vehicle-treated devalue
sessions with increases in both correct (p=0.007, Fig. 1a;
p=0.001, Fig. 2a) and collection (p=0.002, Fig. 1b;
p<0.001, Fig. 2b) latencies (Figs. 1b and 2b). There was a
trend towards a main effect of SESSION in the first group for
omissions (F(1, 11)=4.48, p=0.058, Fig. 1d) and a main ef-
fect of SESSION in the second group (F(1, 10)=5.54, p=
0.040, Fig. 2d). Post hoc pairwise comparisons for the second
group showed a significant devalue effect under vehicle treat-
ment (p=0.02).
Diazepam treatment did not specifically alter the SNC ef-
fect in the first cohort although post hoc pairwise comparison
for correct latency suggested a trend towards an attenuation at
the highest dose tested (1.0 mg/kg, p=0.087). In the second
cohort, there was no main effect of DOSE (F(2, 20)=
1.27, p=0.302) but a trend towards a SESSION–DOSE
interaction for correct latency (F(2, 20)=3.34, p=0.056),
and post hoc pairwise comparisons revealed a signifi-
cant attenuation of the devalue effect at 0.3 mg/kg dose
(p=0.019, Fig. 2a). There were no significant effects on
collection latency or premature responses observed for
either cohort (Figs. 1b and 2b, c).
Buspirone There were no specific effects of buspirone treat-
ment on the SNC effect. A trend to an SNC effect was ob-
served between baseline and devalue sessions with main
effects of SESSION observed for correct (F(1, 11)=
3.44, p=0.090, Fig. 3a) and collection (F(1, 11)=4.50,
p=0.057, Fig. 3b) latencies suggesting a devalue effect. Post
hoc pairwise comparison revealed a significant devalue effect
for correct latency (p<0.001, Fig. 3a) and suggested a trend
towards a collection latency devalue effect under vehicle treat-
ment (p=0.055, Fig. 3b). There was no effect of SESSION for
premature response or omissions. There was a main effect of
DOSE on correct latency (F(1.504, 16.542)=19.38, p<0.001,
Fig. 3a), premature responses (F(1.587, 17.458)=23.70,
p<0.001, Fig. 3c) and number of omissions (F(1.205,
13.253)=10.96, p=0.004, Fig. 3d). Post hoc analysis revealed
Fig. 1 Effects of systemic
treatment with diazepam
(0.0–1.0 mg/kg, i.p.) on
performance variables in operant
SNC in the first cohort of rats
tested. There was a significant
main effect of SESSION for both
correct and collection latencies.
No significant effect of DOSE
was observed on any of the
measured parameters. Results are
shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05, **p<0.01 pairwise
comparison between baseline and
devalue session following vehicle
pretreatment
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that, compared to vehicle, 3.0 mg/kg buspirone significantly
slowed correct latency under both baseline (p=0.003) and
devalue (p=0.013) conditions (Fig. 3a). Both doses of
buspirone reduced premature responding in comparison to
vehicle in devalue sessions (1.0 mg/kg, p=0.045; 3.0 mg/kg,
p<0.001, Fig. 3c). In baseline sessions, 3.0 mg/kg also de-
creased premature responding in comparison to vehicle
(p<0.001, Fig. 3c). Post hoc analysis suggested that collection
latency was increased at the highest dose (3.0 mg/kg) in the
baseline session (p=0.046, Fig. 3b). The highest dose signif-
icantly increased omissions in the baseline sessions (p=0.029)
and tended to increase in the devalue sessions (p=0.059)
(Fig. 3d). No SESSION–DOSE interaction was observed for
any variable.
Citalopram There were no specific effects of citalopram on
the devalue effect. For correct latency, there was no main
effect of SESSION,DOSE or SESSION–DOSE although post
hoc pairwise comparison revealed a significant devalue effect
for vehicle-treated baseline versus devalue sessions (p=0.031,
Fig. 4a). Collection latency was significantly affected by
SESSION (F(1, 11)=17.51, p=0.002) with a devalue effect
seen between vehicle-treated sessions (p=0.005, Fig 4b),
but no effect of DOSE or SESSION–DOSE was ob-
served. There was an effect of SESSION for premature
responses (F(1, 11)=6.00, p=0.032, Fig. 4c) and a trend for
omitted trials (F(1, 11)=4.00, p=0.071, Fig. 4d) with animals
showing a tendency to make fewer premature responses
(p=0.069, Fig. 4c) and more omissions (p=0.044,
Fig. 4d) on devalue sessions. There was a significant main
effect of DOSE for premature responses (F(2, 22)=5.93, p=
0.009, Fig. 4c), with a significant decrease from vehicle in the
baseline session with 1.0 mg/kg (p=0.028, Fig. 4c). A signif-
icant SESSION–DOSE interaction for omissions (F(1.104,
12.148)=6.13, p=0.027) was observed but no significant
main effect of DOSE (F(1.120, 12.324)=3.43, p=0.085).
Post hoc pairwise comparisons showed a difference in omis-
sions between vehicle and each of the doses tested during
devalue but not baseline sessions (Veh vs 0.3 mg/kg,
p=0.044; Veh vs 1.0 mg/kg, p=0.039, Fig. 4d).
Effects of acute administration of anxiogenic drug treatments
FG7142 The highest dose (5.5 mg/kg) of FG7142 slowed
collection latencies and reduced premature responses during
both sessions but only increased correct latencies and omis-
sions during the baseline session. There was a main effect of
DOSE (F(1.373, 15.098)=10.26, p=0.003) and a SESSION–
DOSE interaction (F(1.466, 16.128)=9.87, p=0.003) for cor-
rect latency although no main effect of SESSION. Post hoc
pairwise comparisons revealed a significant devalue effect
between vehicle-treated sessions (p=0.009, Fig. 5a) and a
Fig. 2 Effects of systemic
treatment with diazepam
(0.0–1.0 mg/kg, i.p.) on
performance variables in operant
SNC in the second cohort of rats
tested. There was a significant
main effect of SESSION for
correct latency, collection latency
and omissions. Diazepam
(0.3 mg/kg) significantly
attenuated the SNC effect on
correct latency. There was no
effect of DOSE on the other
variable parameters. Results are
shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05, **p<0.01, ***p<0.001
pairwise comparison between
baseline and devalue session
following vehicle pretreatment.
#p<0.05 pairwise comparisons
vehicle vs drug on baseline or
devalue sessions
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slowing of correct latency at the highest dose of FG7142 dur-
ing baseline sessions (p=0.003, Fig. 5a). There was a main
effect of SESSION for collection latency (F(1, 11)=5.85, p=
0.034, Fig. 5b) with post hoc analysis showing a significant
devalue effect at the vehicle dose (p<0.001). No main effect
of SESSION was observed for omissions, but there was a
trend towards an effect on premature (F(1, 11)=3.75, p=
0.079, Fig. 5c). A significant main effect of DOSE was ob-
served for premature responding (F(2, 22)=11.08, p<0.001,
Fig. 5c) and a SESSION–DOSE interaction (F(2, 22)=3.56,
p=0.046). The highest dose of FG7142 caused a reduction in
premature responding compared to vehicle treatment on base-
line sessions (p=0.002, Fig. 5c) and devalue sessions (p=
0.046, Fig. 5c). There was also a main effect of DOSE for
omitted responses (F(1.217, 13.392)=3.96, p=0.034,
Fig. 5d), and post hoc pairwise comparisons showed a trend
towards increased omissions in the baseline session at the
highest dose used (p=0.056).
Yohimbine Treatment with yohimbine induced a dose-
dependent increase in response, and collection latencies under
baseline conditions but no interactions with the devalue effect
were observed. At the lowest dose tested (1.0 mg/kg), yohim-
bine also increased premature responding during both baseline
and devalue sessions. There was a main effect of SESSION
observed for correct (F(1, 11)=9.26, p=0.011, Fig. 6a) and
collection latency (F(1, 11)=13.29, p=0.004, Fig. 6b)
reflecting an SNC effect. Post hoc comparisons showed a
significant devalue effect between sessions following vehicle
treatment (correct p<0.001 and collection p=0.006).
Omissions and premature responses were not affected by
SESSION (Fig. 6c, d). There was a main effect of DOSE seen
for all variables: correct latency (F(3, 33)=4.70, p=0.008,
Fig. 6a), collection latency (F(1.702, 18.723)=9.89, p=
0.002, Fig. 6b), premature responding (F(3, 33)=12.61,
p<0.001, Fig. 6c) and omissions (F(1.544, 16.987)=4.23,
p=0.041, Fig. 6d). Post hoc analysis showed that the highest
dose of yohimbine (6.0 mg/kg) slowed correct latency on
baseline sessions (p=0.004) but not on devalue sessions (p=
0.773). Both 1.0 mg/kg and 3.0 mg/kg of yohimbine increased
premature responding compared to vehicle on both baseline
and devalue sessions (1.0 mg/kg (baseline p<0.001 and de-
value p=0.002) and 3.0 mg/kg (baseline p=0.042 and devalue
p=0.003)), but there was no main effect of SESSION or SESS
ION–DOSE interaction for this variable. There was also a
SESSION–DOSE interaction (F(1.647, 18.114)=5.98, p=
0.014) for omissions, and 6.0-mg/kg yohimbine significantly
increased omissions in the baseline session (p=0.042).
Fig. 3 Effects of systemic
treatment with buspirone
(0.0–3.0 mg/kg, i.p.) on
performance variables in operant
SNC. No significant effects of
SESSION on any variable
parameter were observed, but the
SNC effect was seen at vehicle for
both correct and collection
latencies. Buspirone (3.0 mg/kg)
significantly increased correct
latency in both baseline and
devalue sessions. This dose
significantly decreased premature
responding in both sessions and
increased omissions in the
baseline session. Results are
shown as mean±SEM, n=12
animals per group, within-subject,
***p<0.001 pairwise comparison
between baseline and devalue
session following vehicle
pretreatment #p<0.05, #p<0.01,
#p<0.001 pairwise comparison
vehicle vs drug on baseline or
devalue sessions
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Effects of acute administration of dopaminergic drugs
Amphetamine Amphetamine treatment induced a specific at-
tenuation of the devalue effect on both correct latency and
premature responding. There was a main effect of SESSION
for correct (F(1, 11)=15.68, p=0.002, Fig. 7a) and collection
(F(1, 11)=21.33, p=0.010, Fig. 7b) latencies reflecting the
devalue effect. Post hoc comparisons revealed an increase
in latencies during vehicle-treated devalue sessions (cor-
rect p=0.002 and collection p=0.030). For correct laten-
cy, no main effect of DOSE was observed; however, a
SESSION–DOSE interaction was seen (F(2, 22)=5.59,
p=0.011) suggesting a specific effect of treatment on
devalue sessions. Post hoc pairwise comparisons sug-
gested a significant attenuation of correct latency at
the highest dose used (0.3 mg/kg, p=0.042). No effect
of DOSE or SESSION–DOSE interaction was observed
for collection latency suggesting that the effects of am-
phetamine on the SNC effect were specific to correct
latency. There was a main effect of SESSION for pre-
mature responses (F(1, 11)=18.66, p=0.001, Fig. 7c)
but not omitted trials (Fig. 7d) and no significant effect
of DOSE or SESSION–DOSE interaction on either. Post hoc
analysis of the amphetamine study revealed a significant
decrease in the devalue session in premature responses at the
highest dose used (p=0.024). Amphetamine did not have any
significant effects on omissions.
Alpha-flupenthixol Treatment with alpha-flupenthixol specif-
ically attenuated the effect of devalue on correct latency and
premature responding at the lowest dose tested (0.1 mg/kg)
although some more general impairments were seen at higher
doses. There was a main effect of SESSION for correct (F(1,
11)=8.00, p=0.016, Fig. 8a) and collection (F(1, 11)=12.08,
p=0.005, Fig. 8b) latencies reflecting the devalue effect. Post
hoc comparisons revealed an increase in correct latency dur-
ing vehicle-treated devalue sessions (p=0.036) but not collec-
tion latency (p=0.113). A main effect of SESSION was also
observed for premature responses (F(1, 11)=7.41, p=0.020,
Fig. 8c) and omitted trials (F(1, 11)=16.04, p=0.002, Fig. 8d).
Treatment with alpha-flupenthixol potentiated the devalue ef-
fect on correct but not collection latencies. A main effect of
DOSE (F(1.334, 14.672)=5.95, p=0.021, Fig. 6a) was ob-
served for correct latency. Both 0.1- and 0.3-mg/kg alpha-
flupenthixol increased correct latencies in the devalue session
only when compared to vehicle (0.1 mg/kg, p=0.002 and
0.3 mg/kg, p=0.008). A trend towards increased latency at
0.3 mg/kg compared to vehicle was also seen in the baseline
Fig. 4 Effects of systemic
treatment with citalopram
(0.0–1.0 mg/kg, i.p.) on
performance variables in operant
SNC. No significant main effect
of citalopram DOSE was seen for
any of the recorded variables. A
significant main effect of SESS
ION was seen for correct and
collection latency. Results are
shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05, **p<0.01 pairwise
comparison between baseline and
devalue session following vehicle
pretreatment #p<0.05 pairwise
comparison vehicle vs drug on
baseline or devalue sessions
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session (p=0.056). There was no main effect of DOSE or
SESSION–DOSE interaction for collection latency suggest-
ing that the effects of treatment on the SNC effect were re-
stricted to correct latency. There was a main effect of DOSE
(F(2, 22)=5.23, p=0.014, Fig. 8c) for premature responses
with a reduction in premature responding during devalue ses-
sions with 0.1 mg/kg (p=0.008) and 0.3 mg/kg (p=0.021).
There was also a trend towards attenuation of premature
responding in the baseline session at 0.1 mg/kg (p=0.058).
A main effect of SESSION (F(1, 11)=16.04, p=0.002),
DOSE F(1.207, 13.273)=12.15, p=0.003) and SESSION–
DOSE interaction F(1.144, 12.583)=11.64, p=0.004) was ob-
served for omissions (Fig. 8d). In the devalue sessions, 0.3-
mg/kg alpha-flupenthixol increased omissions from vehicle
(p=0.002).
Discussion
These data suggest that the devalue effect observed in this
operant SNC task involves a dopaminergic mechanism which
can be attenuated or potentiated by treatments which increase
dopamine levels or antagonise dopamine receptors respective-
ly. The relationship between drug-induced affective states and
the SNC effect is less clear. Results with diazepam were in-
conclusive with one cohort showing an attenuated SNC effect
following treatment whilst in the other group, the observed
attenuation failed to reach significance. The results for
buspirone and citalopram suggest a lack of effect of drugs
which act at the 5-HT1A receptor (partial agonism) or as a
serotonin reuptake inhibitor following acute administration.
However, these results do not preclude a role for other sero-
tonin receptors or an effect if the treatments were given
chronically. The anxiolytic effects of both buspirone and
citalopram in the clinic are only observed following repeated
administration (Goa andWard 1986; Gorman et al. 2002). The
anxiogenic effects of FG7142 and yohimbine were not associ-
ated with any specific change in the SNC effect, suggesting
that drug-induced anxiety-like states do not lead to any specific
potentiation of the SNC effect in this task. Interestingly, both
these treatments seemed to have a greater effect during the
baseline rather than devalue sessions although the reasons for
this are unclear. The effects of amphetamine and alpha-
flupenthixol suggest that the SNC effect on correct latency is
sensitive to modulation by dopaminergic intervention treat-
ments whilst the SNC effect of collection latency is unaffected.
A similar result was also seen for diazepam in the cohort where
an attenuated SNC effect was observed.
Fig. 5 Effects of systemic
treatment with FG7142
(0.0–5.5 mg/kg, i.p.) on
performance variables in operant
SNC. A significant main effect of
DOSE was observed for correct
latency and premature
responding. No main effect of
SESSION was seen for any of the
four recorded variables. Results
are shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05, **p<0.01, ***p<0.001
pairwise comparison between
baseline and devalue session
following vehicle pretreatment
#p<0.05, ##p<0.01 pairwise
comparison vehicle vs drug on
baseline or devalue sessions
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The SNC effect has previously been observed in animals
performing tasks where consummatory behaviour or latency
on a runway has been the main variable used to observe the
devalue effect (Mitchell and Flaherty 2005; Rosas et al. 2007).
This operant nose-poke task allows us to observe the devalue
effect across a wider range of variables and has the potential to
achieve a more comprehensive interpretation of the SNC.
Consistent with our previous study (Mitchell et al. 2012),
animals trained to receive a four-pellet reward showed re-
duced response and collection latency following devalue. In
most of the studies, the number of omissions increased whilst
the number of premature responses decreased, although the
latter changes were less consistent. In all studies, animals con-
tinued to perform the task and completed all trials irrespective
of treatment or the session. Based on previous studies using
the 5CSRTT, these increases in response and collection laten-
cy most likely reflect a reduction in motivation to make a
response to obtain the reduced value reward and to collect this
reward once it has been delivered. The increase in the number
of omitted trials also suggests effects on cognitive processes
such as attention. The changes in premature responding ap-
pear to correspond with motivation for the reward as these
tend to be reduced when the value is downshifted. Animals
are still performing the task and completing all trials, but the
impact of devaluing the outcome may also reduce their atten-
tion and therefore overall accuracy. It would be interesting to
test this further using a full five-whole version of this SNC
task where visuospatial attention is also tested.
Amphetamine, an indirect dopamine agonist, attenuated
the SNC effect on correct latency and premature responding.
In contrast, the D1/D2 antagonist, alpha-flupenthixol, poten-
tiated the SNC effect on these variables. No effects on collec-
tion latency were observed although a clear devalue effect was
present in all the studies. These results compliment findings
that the devaluation of a reward decreases the dopamine re-
sponse in the nucleus accumbens in consummatory SNC
(Genn et al. 2004). These findings are also consistent with
previous studies which have shown that animals withdrawn
from the psychostimulant amphetamine show an exaggerated
SNC effect, which may be related to the effects of drug with-
drawal on the dopamine system (Barr and Phillips 2002). Our
version of an SNC task allows distinction between drive to
respond to obtain a reward (correct latency, premature and
omissions) and motivation to collect a reward (collection la-
tency). In this study, it was found that the latency to respond
for the reward but not the latency to collect reward was mod-
ulated by dopaminergic manipulations during the devalue ses-
sions. This observation corresponds with previous work using
Fig. 6 Effects of systemic
treatment with yohimbine
(0.0–6.0 mg/kg, i.p.) on
performance variables in operant
SNC. A main effect of SESSION
was seen for both correct and
collection latencies. Yohimbine
(6.0 mg/kg) significantly
increased correct latency,
collection latency and omissions
in the baseline sessions.
1.0 mg/kg and 3.0 mg/kg
increased percentage premature in
both baseline and devalue
sessions. Results are shown for as
mean±SEM, n=12 animals per
group, within-subject, *p<0.05,
**p<0.01, ***p<0.001 pairwise
comparison between baseline and
devalue session following vehicle
pretreatment #p<0.05, ##p<0.01,
###p<0.001 pairwise comparison
vehicle vs drug on baseline or
devalue sessions
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the same task with manipulations of affective state (Mitchell
et al. 2012). Together with previous studies investigating do-
paminergic mechanisms involved in the 5CSRTT (Robbins
2002), our findings suggest that differential mechanisms con-
tribute to the devalue effect associated with the drive to obtain
reward compared with those modulating motivation to collect
the reward once dispensed. In our study, dopaminergic signal-
ling was only involved in response latency, suggesting that the
SNC effect on motivation to collect reward involves a
nondopaminergic mechanism. Interestingly, previous studies
have found links between the SNC effect and opioid system
which is also strongly connected to the regulation of dopa-
mine levels in the reward system in the CNS (Devine et al.
1993). The opioid agonists morphine and DPDPE both atten-
uate the SNC effect (Rowan and Flaherty 1987; Wood et al.
2005) whilst the opioid antagonist naloxone potentiates it
(Pellegrini et al. 2005).
Serotonergic modulation did not significantly influ-
ence the SNC effect in our studies. Neither acute treat-
ment with the selective serotonin reuptake inhibitor
(SSRI) antidepressant citalopram nor 5-HT1A partial agonist
and anxiolyticbuspirone had a significant specific effect on
correct or collection latencies. Citalopram is an anxiolytic in
both conditioned freezing (Inoue et al. 1996) and shock-
induced modulation (Schreiber et al. 1998), but it is an
anxiogenic in the elevated plus maze (Pollier et al. 2000)
and the light–dark exploratory test (Sanchez and Meier
1997). However, in this study, no specific effects were seen
suggesting that our operant SNC is not sensitive to SSRIs.
Results presented here also show no specific effect of
buspirone in the task. The highest dose of buspirone used
did affect latencies in both types of session as well as reducing
premature responses and increasing the number of omissions.
As these effects occurred during both trial types, they are more
likely due to nonspecific effects such as mild sedation (Vaidya
et al. 2005; Pavlakovic et al. 2009). Similar to our findings,
neither acute nor chronic buspirone had any effect on SNC in
either a one-way avoidance learning task (Torres et al. 1995)
or in consummatory SNC (Flaherty et al. 1990).
One of the more widely studied receptor systems linked to
SNC and anxiety is the benzodiazepine receptor (Flaherty
et al. 1980; Morales et al. 1992; Nikiforuk and Popik 2009).
However, in our study, the benzodiazepine agonist diazepam
was found to either attenuate or have no specific action on the
SNC effect depending on the cohort of rats. It is difficult to
draw any conclusions from these differences, although diaze-
pam was apparently more effective in the cohort that was
tested at the end of the experiment after extensive training
Fig. 7 Effects of systemic
treatment with amphetamine
(0.0–0.3 mg/kg, i.p.) on
performance variables in operant
SNC. Amphetamine significantly
attenuated the SNC effect on
correct latency but not collection
latency. There was a significant
increase in premature responses in
the devalue session only. No
significant changes were seen
with omissions. Results are
shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05, **p<0.01 pairwise
comparison between baseline and
devalue session following vehicle
pretreatment #p<0.05 pairwise
comparison vehicle vs drug on
baseline or devalue sessions
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and testing. In this cohort, there was a specific attenuation of
the devalue effect at 0.3 mg/kg diazepam. Similar to the do-
paminergic treatments, the effect was specific to correct laten-
cy, and no effect on collection latency or other variables was
observed. This dose of drug also had no effect on performance
measures during baseline testing suggesting a specific interac-
tion with the devalue effect. Previous studies have also found
a benzodiazepine-induced attenuation of the SNC effect. The
benzodiazepine agonist, chlordiazepoxide, has been shown to
be effective from the first day of reinforcer downshift in a
lever press task (Nikiforuk and Popik 2009) and in reducing
contrast from the second postshift day in consummatory con-
trast protocols (Flaherty et al. 1980).
In terms of the relationship between increased anxiety and
the SNC effect, rats bred for high anxiety exhibit a greater
SNC effect in an instrumental runway task (Rosas et al.
2007). From this, it was hypothesised that pretreatment with
anxiogenic drugs would potentiate the SNC effect. However,
in this study and task design, the benzodiazepine inverse ag-
onist, FG7142, and α2-adrenoceptor antagonist, yohimbine,
did not specifically potentiate the SNC effect. The highest
dose of FG7142 increased correct latency and reduced prema-
ture responding on baseline sessions only, which may be a
result of lower motivation from effects of FG7142 on appetite
(Cottone et al. 2007). At the highest dose of yohimbine, both
correct and collection latencies were increased on baseline
sessions, which may indicate an anxiogenic effect of yohim-
bine influencing general task performance. Interestingly, yo-
himbine increased premature responses during both baseline
and devalue sessions which were opposite to the effect seen
with FG7142. This increase in premature responding may
involve a specific effect on impulse control and the proposal
that α2-adrencoceptors play an important role in regulating
this behaviour (Franowicz et al. 2002; Arnsten 2011).
In our study, we did not use a separate, non-shifted control
group which may represent a potential limitation. In most
previous studies investigating the SNC effect (Flaherty et al.
1980; Barr and Philips 2002; Genn et al. 2004; Mitchell and
Flaherty 2005; Pellegrini et al. 2005; Burman et al. 2008;
Nikiforuk and Popik 2009), a control group which only ever
received the low-value reward was included. This control is
often included for two reasons: first, to demonstrate a devalue
effect defined as a shift to a level below that of animals which
only ever received the lower value reward (Crespi 1942) and
second, to provide a treatment control for between-subject
study designs. Our previous work using this task has shown
the devalue effect against a one-pellet control group (Mitchell
et al. 2012), but a within-subject design for experimental ma-
nipulations, as in our current study, potentially negated the
need for a lower value reward control group. One limitation
Fig. 8 Effects of systemic
treatment with alpha-flupenthixol
(0.0–0.3 mg/kg, i.p.) on perfor-
mance variables in operant SNC.
Alpha-flupenthixol significantly
potentiated the SNC effect on
correct latency but not collection
latency. There was a significant
decrease in premature responding
and an increase in omissions in
the devalue session only. Results
are shown as mean±SEM, n=12
animals per group, within-subject,
*p<0.05 pairwise comparison
between baseline and devalue
session following vehicle pre-
treatment #p<0.05, #p<0.01
pairwise comparison vehicle vs
drug on baseline or devalue
sessions
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of this method is that it is not possible to determine if the drugs
would have shown different effects in animals which only
received low- or high-value reward throughout.
Another limitation of this study may be that premature
responding was not stable in cohort 1 and that premature re-
sponses were not consistently reduced during devalue. This
may suggest that this measure is not the most reliable indica-
tion of the SNC effect in this task. In contrast, all other mea-
sures were stable throughout the study, and these measures
form the main basis for the conclusions presented in this
paper.
Together, results presented here suggest that the SNC
effect is at least partially mediated by dopaminergic sig-
nalling. Dopamine is known to play an important role in
reward processing, and the recognition and subsequent
adaptive changes in behaviour during devalue may reflect
changes in dopamine signalling (for review, see Schultz
2010). For example, studies in monkeys have shown that
learning of a reward predictive cue results in firing of
dopamine neurones in response to presentation of the
cue. However, if the subsequent reward is not delivered,
a reduction in dopamine neuronal f ir ing is seen
(Mirenowicz and Schultz 1994). Dopamine is also thought
to play a role in affective behaviour with anhedonia being
linked to mood disorders both in humans and animals
(DSM-V; Cryan and Slattery 2007; Nestler and Hyman
2010). Although we did not see any specific effects with
the anxiogenic manipulations used in this task and results
with the serotonergic drugs were also negative, the results
for diazepam suggest that there may be some relationship
between affective state and the SNC effect. Previous stud-
ies which have shown a link between the magnitude of
the devalue effects and affective state generally used long-
term manipulations such as chronic mild stress (Burman
et al. 2008). It may therefore be that the SNC effect is
sensitive to negative affective states more akin to depres-
sion than anxiety. In our study, all drugs were adminis-
tered acutely, and further studies using chronic drug treat-
ments are needed to address this issue. It would also be
interesting to look at these treatments in animals who have
a depression-like phenotype such as those exposed to
chronic mild stress (Cryan and Slattery 2007; Nestler
and Hyman 2010).
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